GlaxoSmithKline News and Research

RSS

Pfizer, GlaxoSmithKline to increase sales of pneumococcal vaccines through GAVI

Pharmaceutical companies Pfizer and GlaxoSmithKline are increasing their sales of reduced-cost pneumonia vaccines to developing countries through the GAVI Alliance "by more than 50 percent, marking the scale-up of an international program to protect millions of children," Reuters reports.

20 Dec 2011

GSK initiates rhACE2 phase IIa study for Acute Lung Injury

APEIRON Biologics AG announced today that GlaxoSmithKline, exclusive, worldwide licensee for Apeiron's new investigational recombinant human Angiotensin Converting Enzyme 2 (rhACE2, name: GSK2586881, formerly APN01), has initiated a phase IIa study in patients suffering from Acute Lung Injury.

19 Dec 2011

Parents blame swine flu vaccine for son’s narcolepsy

A six year old boy’s parents have claimed that he developed narcolepsy after a swine flu vaccination. Caroline Hadfield said son Josh lost muscle control and started sleeping up to 19 hours a day three weeks after being given Pandemrix nearly two years ago.

12 Dec 2011

FDA approves changes to REMS for Nplate and Promacta

The approval of changes to the Risk Evaluation and Mitigation Strategies (REMS) for both Nplate (romiplostim) and Promacta (eltrombopag) was announced by the U.S. Food and Drug Administration.

7 Dec 2011

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Unigene Laboratories, Inc. today announced that the Company terminated its amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GlaxoSmithKline (GSK) pertaining to an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

5 Dec 2011

Abbott, GSK expand collaboration to develop additional companion diagnostic test

Abbott announced today that it will expand its existing agreement with GlaxoSmithKline Biologicals S.A. to include the development of an additional companion diagnostic test in support of GSK's cancer immunotherapy research program.

29 Nov 2011

Mass immunization with cervical cancer vaccine switched to a more effective variety

Cervarix is currently offered to girls aged 12 and 13 years to protect against strains of the sexually transmitted human papillomavirus (HPV), which causes most cases of cancer of the cervix, the neck of the womb. Cervarix was picked by the Labour government for the first four-year phase of the NHS programme in 2008 because it offered ‘best overall value’ and more than five million doses have been given.

27 Nov 2011

University of Rochester receives U.S. patent for HPV vaccine research

The University of Rochester has been awarded a U.S. patent for research essential to both human papillomavirus vaccines on the market.

23 Nov 2011

Mycophenolate mofetil superior to azathioprine for lupus nephritis

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

17 Nov 2011

Pneumococcal vaccine Prevnar13 effective in seniors

Pneumococcal disease kills millions worldwide and the largest affected groups are children and the elderly. Federal health scientists now assure that the popular pneumococcal vaccine Prevnar is at least as effective as a rival vaccine at protecting adults from the sometimes-deadly infection.

15 Nov 2011

Ligand third quarter total revenues decrease to $5.7 million

Ligand Pharmaceuticals Incorporated today announced financial results for the three and nine months ended September 30, 2011 and provided a business update.

9 Nov 2011

Positive results from ChemoCentryx CCX354 Phase II study on RA

ChemoCentryx, Inc., today announced that it reported positive Phase II results for CCX354 at the Annual Meeting of the American College of Rheumatology.

9 Nov 2011

Glaxo pays $3 billion to settle investigations involving alleged marketing missteps and Medicaid fraud

GlaxoSmithKline PLC said it will pay the U.S. government $3 billion to settle several long-running criminal and civil investigations into the company, including allegations that Glaxo marketed some drugs illegally and defrauded the Medicaid program. The settlement will also cover a Department of Justice probe into Glaxo's development and marketing of the diabetes drug Avandia, which has been linked to heart attack risks.

4 Nov 2011

POZEN third quarter revenue increases to $4.9 million

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the third quarter ended September 30, 2011.

3 Nov 2011

First Edition: November 3, 2011

Today's headlines include reports about a bipartisan group of lawmakers who are urging the super committee to consider "all options."

3 Nov 2011

GSK, Alnylam collaborate to apply VaxiRNA technology for influenza vaccine production

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today it has formed a collaboration with GlaxoSmithKline (GSK) focused on Alnylam's VaxiRNATM technology for certain GSK vaccine products, including influenza. VaxiRNA is a new RNAi technology for the enhanced production of viruses used in the manufacture of vaccine products. GSK, a leading vaccine manufacturer, is the first company to form a collaboration accessing this new platform.

2 Nov 2011

Virtual platform for intellectual property sharing aims to speed development of drug treatments

"The World Intellectual Property Organization (WIPO) launched a consortium on Wednesday that would allow the public and private sector to share intellectual property to promote the development of new drugs to treat diseases such as malaria," Reuters reports.

28 Oct 2011

Ambitious vision, lasting investment in science can save countless lives

In this post in the American Society of Tropical Medicine and Hygiene's "ASTMH Blog," Rick Steketee, science director of PATH's Malaria Control Program and ASTMH council member, responds to the results of the RTS,S malaria vaccine trial, writing, "It's milestones like this week's findings that remind us all that ambitious vision and a lasting investment in science can yield the tests, treatments and tools to save countless lives."

22 Oct 2011

The Guardian interviews GlaxoSmithKline lead researcher about new malaria vaccine

The Guardian features an interview with Moncef Slaoui, now chair of research and development at GlaxoSmithKline, who discusses his 23-year involvement in the research leading to the RTS,S malaria vaccine that has shown to halve the risk of malaria among African children.

21 Oct 2011

Young docs not so keen on immunizations: Survey

A cross-sectional survey of 551 healthcare providers and noted that more recent graduates were less likely to think that vaccines were efficacious said Saad Omer, assistant professor of Emory University in Atlanta. They were also more likely to have doubts about the safety of some vaccines, Omer told reporters at the 49th annual meeting of the Infectious Diseases Society of America (IDSA).

20 Oct 2011